Yoomin Jeon and Siun Kim were awarded the Best Oral Presentation Award at the 2021 KSCPT Conference.The Best Oral Presentation Award aims to recognize outstanding scientific papers delivered through oral presentations at the conference. The awards were given to oral presentations of the paper titled "A Randomized, Double-blind, Placebo- and Active-controlled, Escalating Single-dose Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasians" and "An Annotated Corpus and Natural Language Processing Model for Drug Safety Information Extraction from Free-texts Reporting Adverse Events" for Yoomin and Siun, respectively. 

Yoomin presented the results of a phase 1 clinical trial evaluating the pharmacokinetics and pharmacodynamics of eflapegrastim following subcutaneous administration to healthy subjects. Eflapegrastim (Rolontis®) is a novel, long-acting Granulocyte-Colony Stimulating Factor (G-CSF) being studied as a treatment for neutropenia that utilizes Hanmi's Labscovery, a proprietary platform technology. 

Siun presented an annotated corpus for extracted Korean adverse events using free-texts from the KAERS (Korean Adverse Event Reporting System) database. To this end, Siun Kim developed deep learning models that automatically extract medication and adverse event information, cooperating with MILAB in Seoul National University.

CCADD is breaking the ground for biomedical natural language processing or NLP!

On January 22^nd, 2021, CCADD was nominated by the Ministry of Food and Drug Safety to develop an NLP model that extracts core clinical information from unstructured data in the Korea Adverse Event Reporting System (KAERS). The total research fund amounts to two hundred million Korean won or a hundred and eighty thousand U.S. dollars. The project will be performed in collaboration with the Machine Intelligence lab in the Department of Electrical and Computer Engineering, Seoul National University (Prof. Gyo-Min Jung). 

For starters, CCADD will build a manually annotated dataset, which is indispensable to train and refine any machine learning algorithm including NLP. Next, CCADD plans to build the KAERS-BERT model, an NLP model specifically tuned to handle adverse drug events. The KAERS-BERT model will be pre-trained on KAERS text data, which then will be deployed to extract medical information from free texts, such as hand-written records of adverse events. Once complete, the KAERS-BERT model is expected to address many of the language ambiguities caused by the mixed use of English and Korean in medical domains already peppered with technical and medical jargons. The KAERS-BERT model will significantly improve the performance and the outcome of NLP tasks when extracting information from clinical notes written in English and Korean. 

Prof. Howard Lee, the PI of the grant, congratulated the team, saying "The grant awarding is timely and important since it will help CCADD enter a new area of biomedical NLP." At the conclusion of this project, CCADD will once again have secured its place as the leading lab in the field of convergence science between medicine, drug development, and machine learning including NLP. "This certainly provides CCADD with a momentum to transform into a frontrunner in the field", Prof. Lee added.

Dr. Jeong-An Gim has been awarded a government grant from the National Research Foundation (NRF) of Korea on September 1, 2018 to study epigenetic/epigenomic changes after drug treatment. The grant will cover a year and the total research funding is $40,000 or ~40 million Korean Won. The title of Dr. Gim's research was "An Association Study Between the Pharmacoepigenomic Patterns of Drug-metabolizing Enzymes and the Pharmacokinetics of Tacrolimus", which aimed to identify several sensitive genetic regions associated with the pharmacokinetics of tacrolimus, an immunosuppressive agent frequently used in transplant patients. Blood samples for this proposed study have been already collected from two previous studies ( Choi et al., Kim et al., 2017 ), and the samples will be outsourced to Theragen Etex for the next generation sequencing (NGS) analysis. 

The proposed study is the first of its kind applying the state-of-the-art technologies to investigating the epigenetic/epigenomic effect on the exposure to tacrolimus in humans. Dr. Gim has been interested in finding an optimal epigenetic state to maximize the efficacy of a drug while minimizing potential adverse events, and tacrolimus will be his first bet. 

Prof. Lee congratulated Dr. Gim, saying "Converging the principles of clinical pharmacology, genomics, and eipgenetics/epigenomics, we will have a much better understanding how humans handle the administered drug." Prof. Lee added, "Dr. Gim's approach is innovative, and his research exemplifies how convergent approaches can be adopted to solve problems in drug development."